spacer
home > ict > winter 2018 > promising participation
PUBLICATIONS
International Clinical Trials

Promising Participation

In the history of medical research, the concept of patient centricity is a relatively new one. Until a few years ago, the primary focus of most clinical trials was developing drugs for commercial application. Patients were important and necessary to this process, but only because they represented the human connection to data the development team needed to move a drug candidate or treatment option through the regulatory approval process.

Unsurprisingly, patients who did become involved in clinical trials often felt disrespected and unimportant. As the industry accepted that patients’ generally low levels of satisfaction translated into compliance issues and high dropout rates, as well as broadly negative perceptions of clinical research that contribute to the limited participation rates of today, interest began to rise in assessing and addressing patient concerns.

By the mid-2000s, terms such as ‘patient centricity’ and ‘patientcentric trials’ had begun to find their way into publications and presentations. Although precise definitions vary, the underlying concept from the beginning is that providing patients with more information and greater integration into the trial process will lead to greater patient satisfaction and improved outcomes for sponsors, research centres, and patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lea Studer is the Senior Vice President of Marketing Communications at SCORR marketing – a full-service marketing firm in the health sciences industry, and the lead organiser for the Bridging Clinical Research and Clinical Healthcare Collaborative. The collaborative was founded to bring together leaders from pharma, biotechnology, CROs, healthcare organisations, advocacy groups, and the FDA to focus on ways to advance healthcare through bridging regulatory, technology, and people and processes.
spacer
Lea Studer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Introduces Decentralized Clinical Trials Network

10/05/2022  WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, announced the creation of the PPD DCT Network to support global investigators and research sites participating in decentralized clinical trials (DCTs) for pharmaceutical and biotech customers.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement